I have no idea what the value of POH is and anyone who thinks...

I have no idea what the value of POH is and anyone who thinks they do is kidding themselves. Enterprise value is entirely inadequate for valuing a biotech with no cashflow or any commercial deal that puts a $ value on their science.

Also corporate finance departments don't just look at enterprise value, they compare EV to EBITDA and come up with a multiple. I personally don't use or condone this method. I prefer to look at ROE and the percentage of earnings reinvested and paid out as dividends. Basically companies that generate above average returns on equity and that can reinvest a high proportion of their earnings at that rate are companies I'm interested in. And there is POH, which for me is nothing more than pure speculation because their is absolutely no way to put a value on it.